Pharvaris (NASDAQ:PHVS – Get Rating) had its target price reduced by SVB Leerink from $25.00 to $20.00 in a report published on Wednesday, The Fly reports. SVB Leerink currently has an outperform rating on the stock.
Several other research analysts have also commented on PHVS. JMP Securities dropped their price target on shares of Pharvaris from $34.00 to $18.00 and set a mkt outperform rating on the stock in a research note on Tuesday. Morgan Stanley lowered shares of Pharvaris from an overweight rating to an equal weight rating and dropped their price target for the stock from $40.00 to $10.00 in a research note on Tuesday, August 23rd. Oppenheimer dropped their price target on shares of Pharvaris from $48.00 to $22.00 and set an outperform rating on the stock in a research note on Tuesday, August 23rd. Finally, Bank of America lowered shares of Pharvaris from a neutral rating to an underperform rating and dropped their price target for the stock from $26.00 to $13.00 in a research note on Monday, August 22nd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and two have given a buy rating to the company. According to MarketBeat, Pharvaris has a consensus rating of Hold and an average price target of $16.60.
Get
Pharvaris alerts:
Pharvaris Trading Up 0.8 %
Shares of NASDAQ PHVS opened at $9.14 on Wednesday. The firm has a market capitalization of $291.06 million, a PE ratio of -3.52 and a beta of -0.19. The business has a 50-day moving average price of $16.74 and a two-hundred day moving average price of $17.99. Pharvaris has a one year low of $8.55 and a one year high of $27.50.
Pharvaris (NASDAQ:PHVS – Get Rating) last issued its quarterly earnings data on Monday, September 12th. The company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.57) by $0.19. Research analysts anticipate that Pharvaris will post -2.18 EPS for the current year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Bank of America Corp DE grew its position in Pharvaris by 1,054.4% in the 1st quarter. Bank of America Corp DE now owns 5,772 shares of the company's stock worth $105,000 after purchasing an additional 5,272 shares during the last quarter. DAFNA Capital Management LLC grew its position in Pharvaris by 4.7% in the 4th quarter. DAFNA Capital Management LLC now owns 36,720 shares of the company's stock worth $528,000 after purchasing an additional 1,646 shares during the last quarter. Goldman Sachs Group Inc. grew its position in Pharvaris by 2.0% in the 2nd quarter. Goldman Sachs Group Inc. now owns 56,951 shares of the company's stock worth $1,259,000 after purchasing an additional 1,115 shares during the last quarter. Eventide Asset Management LLC grew its position in Pharvaris by 23.6% in the 1st quarter. Eventide Asset Management LLC now owns 302,619 shares of the company's stock worth $5,659,000 after purchasing an additional 57,694 shares during the last quarter. Finally, Novo Holdings A S grew its position in Pharvaris by 23.2% in the 4th quarter. Novo Holdings A S now owns 516,321 shares of the company's stock worth $7,430,000 after purchasing an additional 97,378 shares during the last quarter. 70.21% of the stock is currently owned by institutional investors and hedge funds.
Pharvaris Company Profile
(Get Rating)
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE).
Read More
- Get a free copy of the StockNews.com research report on Pharvaris (PHVS)
- Is This Medical Gear Maker Ready To Continue Its Rally?
- The Five (5) Hottest Stocks To Watch Ahead Of Q3 Earnings
- Has Take-Two Interactive Devolved into a One-Trick Pony?
- Four Cheap Stocks With Interesting Insider Activity
- Can Health Drink Maker Celsius Outrun Its Monster Rival?
Receive News & Ratings for Pharvaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharvaris and related companies with MarketBeat.com's FREE daily email newsletter.
